- Overview:
- This study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of individuals with central precocious puberty.
- Staus:
- Enrolling
- Clinical Description:
- The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart. Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 mL in males.
- Target Age/Sex:
- Females age 2 to 8 years or males age 2 to 9 years
- Benefits:
- Participants will receive at no cost: study product, study materials and study-specific procedures.
- Study Length:
- Approximately 12 Months
- Link:
- ClinicalTrials.gov
